Home
|
Learning Center
|
中文版
Publications
站内成果搜索:
搜索
Phase I/II trial of pemetrexed plus nab-paclitaxel in advanced solid tumor patients with emphasis on non-small cell lung cancer
Phase 2 metabolites of H-hydroxylated amidines (amidoximes): Synthesis, in vitro formation by pig hepatocytes, and mutagenicity testing
Phase variation in the phage growth limitation system of Streptomyces coelicolor A3(2)
Phase II study of combination thalidomide/interleukin-2 therapy plus granulocyte macrophage-colony stimulating factor in patients with metastatic renal cell carcinoma
Phase I trial of PEG-interferon and recombinant IL-2 in patients with metastatic renal cell carcinoma
Phase I dose escalation study of telatinib (BAY 57-9352) in patients with advanced solid tumours
Phase II studies of antiangiogenic four drug regimens for the treatment of advanced renal cell carcinoma: FUNIL-retinoid and the FUNIL-thalidomide protocols
Phase II trial of sorafenib in advanced thyroid cancer
Phase-I study of Innacell gamma delta (TM), an autologous cell-therapy product highly enriched in gamma 9 delta 2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma
Phase II trial of capecitabine and weekly docetaxel in metastatic renal cell carcinoma
Phase II trial of gemcitabine plus capecitabine for metastatic renal cell cancer previously treated with immunotherapy and targeted agents
Phase I/II trial of 5-fluorouracil and a noncytotoxic dose level of suramin in patients with metastatic renal cell carcinoma
Phase-variable expression of a family of glycoproteins imparts a dynamic surface to a symbiont in its human intestinal ecosystem
Phase-controlled growth of metastable Fe5Si3 nanowires by a vapor transport method
Phase 1 study of trebananib (AMG 386), an angiogenesis targeting angiopoietin-1/2 antagonist, in Japanese patients with advanced solid tumors
Phase II Trial of Sorafenib in Combination with Carboplatin and Paclitaxel in Patients with Metastatic Uveal Melanoma: SWOG S0512
Phase I study of sorafenib in combination with docetaxel and prednisone in chemo-na %26lt; ve patients with metastatic castration-resistant prostate cancer
Phase II study of sorafenib in patients with relapsed or refractory lymphoma
Phase I trial of toll-like receptor 9 agonist PF-3512676 with and following rituximab in patients with recurrent indolent and aggressive non-hodgkin's lymphoma
Phase II Study of Sunitinib in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: GORTEC 2006-01
Phase I, dose escalation and pharmacokinetic study of cediranib (RECENTIN (TM)), a highly potent and selective VEGFR signaling inhibitor, in Japanese patients with advanced solid tumors
Phase I Trial of a Combination of the Multikinase Inhibitor Sorafenib and the Farnesyltransferase Inhibitor Tipifarnib in Advanced Malignancies
Phase II Study of Sorafenib in Patients With Sunitinib-Refractory Metastatic Renal Cell Cancer
Phase II Presurgical Feasibility Study of Bevacizumab in Untreated Patients With Metastatic Renal Cell Carcinoma
Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer
Phase II, Multicenter, Uncontrolled Trial of Single-Agent Sorafenib in Patients With Relapsed or Refractory, Advanced Non-Small-Cell Lung Cancer
Phase structure and Hosotani mechanism in gauge theories with compact dimensions revisited
Phase I dose escalation study of MK-0457, a novel Aurora kinase inhibitor, in adult patients with advanced solid tumors
Phase I and Pharmacokinetic Study of CT-322 (BMS-844203), a Targeted Adnectin Inhibitor of VEGFR-2 Based on a Domain of Human Fibronectin
Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of ENMD-2076, a Novel Angiogenic and Aurora Kinase Inhibitor, in Patients with Advanced Solid Tumors
Phase III Trial of Everolimus in Metastatic Renal Cell Carcinoma: Subgroup Analysis of Japanese Patients from RECORD-1
Phase I/II study of sorafenib with anastrozole in patients with hormone receptor positive aromatase inhibitor resistant metastatic breast cancer
Phase 3 Trial of Everolimus for Metastatic Renal Cell Carcinoma Final Results and Analysis of Prognostic Factors
Phase II trial of sorafenib in advanced salivary adenoid cystic carcinoma of the head and neck
Phase II study of G3139, a Bcl-2 antisense oligonucleotide, in combination with dexamethasone and thalidomide in relapsed multiple myeloma patients
Phase behavior and selectivity of DNA-linked nanoparticle assemblies
Phase-shifting photoelasticity using a flatbed scanner
Phase synchronization in temperature and precipitation records
Phase 2 study of canfosfamide in combination with pegylated liposomal doxorubicin in platinum and paclitaxel refractory or resistant epithelial ovarian cancer
Phase I Dose-Escalation Trial of the Oral Investigational Hedgehog Signaling Pathway Inhibitor TAK-441 in Patients with Advanced Solid Tumors
Phase II pilot study of oral dasatinib in patients with higher-risk myelodysplastic syndrome (MDS) who failed conventional therapy
Phase I Study of Temsirolimus in Pediatric Patients With Recurrent/Refractory Solid Tumors
Phase Behavior of Hyperbranched Polymer Systems: Experiments and Application of the Perturbed-Chain Polar SAFT Equation of State
Phase I study of concurrent real-time tumor-tracking thoracic radiation therapy with paclitaxel and carboplatin in locally advanced non-small cell lung cancer
Phase-selective synthesis and phase-conversion of porous aluminum-benzenetricarboxylates with microwave irradiation
Phase I and II Trials of Vinorelbine With Carboplatin for Patients 75 Years of Age or Older With Previously Untreated Non-Small-Cell Lung Cancer
Phase-coherent transport in graphene quantum billiards
Phase I Trial of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Refractory, Locally Advanced or Metastatic Solid Tumors
Phase Separation and Phase Transitions in Multiferroic K0.58FeF3 with the Tetragonal Tungsten Bronze Structure
Phase I/II trial of a biweekly combination of S-1 plus docetaxel in patients with previously treated non-small cell lung cancer (KRSG-0601)
Phase II Study of Nab-Paclitaxel and Bevacizumab as First-line Therapy for Patients with Unresectable Stage III and IV Melanoma
Phase I/II Study of PHY906/Capecitabine in Advanced Hepatocellular Carcinoma
Phase I clinical and laboratory evaluation of topotecan and cytarabine in patients with acute leukemia
Phase I evaluation of telatinib, a VEGF receptor tyrosine kinase inhibitor, in combination with bevacizumab in subjects with advanced solid tumors
Phase II, Multicenter, Uncontrolled Trial of Single-agent Capecitabine in Patients With Non-clear Cell Metastatic Renal Cell Carcinoma
Phase 1 Trial of Everolimus Plus Sunitinib in Patients With Metastatic Renal Cell Carcinoma
Phase 2 trial of linifanib (ABT-869) in patients with advanced renal cell cancer after sunitinib failure
Phase II trial of temsirolimus in children with high-grade glioma, neuroblastoma and rhabdomyosarcoma
Phase III Trial of Vandetanib Compared With Erlotinib in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer
Phase II study of S-1, a novel oral fluoropyrimidine, and biweekly administration of docetaxel for previously treated advanced non-small-cell lung cancer
Phase III Trial Comparing Vinflunine With Docetaxel in Second-Line Advanced Non-Small-Cell Lung Cancer Previously Treated With Platinum-Containing Chemotherapy
Phase evolution of Li2ND, LiD and LiND2 in hydriding/dehydriding of Li3N
Phase I dose escalation trial of docetaxel plus curcumin in patients with advanced and metastatic breast cancer
Phase II trial of non-pegylated liposomal doxorubicin and low-dose prednisone in second-line chemotherapy for hormone-refractory prostate cancer
Phase 2 study of neoadjuvant docetaxel plus bevacizumab in patients with high-risk localized prostate cancer
Phase II trial of erlotinib in women with squamous cell carcinoma of the vulva
Phase III trial of gemcitabine plus docetaxel versus capecitabine plus docetaxel with planned crossover to the alternate single agent in metastatic breast cancer